Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial. | MicrobiomeTrials
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-06-05Est. Completion: 2030-03-31
Enrollment target: 320 participants
Locations
CH Bayonne, Bayonne, France
Institut Bergonié, Bordeaux, France
CHP Brest - Pasteur, Brest, France
Hôpital Henri-Mondor, Créteil, France
GHM Cancérologie - Institut Daniel Hollard, Grenoble, France
Hôpital Franco-Britannique, Levallois-Perret, France
GHBS - Hôpital du Scorff, Lorient, France
Centre De Cancérologie Du Grand Montpellier, Montpellier, France
Institut du Cancer de Montpellier - Val d'Aurelle (ICM), Montpellier, France
CHU Nîmes, Nîmes, France
Hospices Civils de Lyon - HCL, Paris, France
Hôpital Européen Georges Pompidou, Paris, France
Hôpital Paris Saint-Joseph, Paris, France
Hôpital Pitié-Salpêtrière, Paris, France
CHU Poitiers, Poitiers, France
Institut Godinot, Reims, France
CHU de Rennes, Rennes, France
Polyclinique Saint Georges, Saint-Georges-de-Didonne, France
CHP Saint Gregoire, Saint-Grégoire, France
Other microbiome trials you might be interested in